Skip to main content
Premium Trial:

Request an Annual Quote

MediSapiens, Bayer Developing Platform for Cancer Genomic Data Analysis

NEW YORK (GenomeWeb News) – MediSapiens today announced that it and Bayer HealthCare Pharmaceuticals have reached an agreement to develop a platform for the analysis of cancer genomics data.

"Genomics data is increasingly used both in preclinical and clinical research, but lacks software tools that can be adapted to various research environments," Tommi Pisto, CEO of MediSapiens, said in a statement. "Our flexible platform and know-how in designing software for demanding bioinformatics environments will be tailored to meet the needs of oncology research at Bayer HealthCare Pharmaceuticals."

Financial and other terms were not disclosed.

MediSapiens is a startup bioinformatics firm based in Helsinki. It received $1 million in seed funding in the spring of 2010.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.